ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Biohaven (BHVN)
Biohaven stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NYSE
$14.45▲ +4.11%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Biohaven in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Biohaven
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Biohaven a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $11.68 and $16.59; in 9 out of 10, between $8.57 and $22.63. Estimated annual volatility is 109%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.9B
- 52-week high
- $18.57
- 52-week low
- $7.48
- Revenue (12 months)
- $0.0M
- Free cash flow (12 months)
- $-256M
- Beta
- 3.17
What this means
ATLAS does not publish a fair value for BHVN right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks BHVN has traded between $7.48 and $18.57. Today it is 22.2% below that high and 93% above its low.
Its beta is 3.17: it tends to move more than the market, both up and down.
About the company
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology.
Want to see everything about Biohaven?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Biohaven do?
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology.
What is the chance BHVN goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, BHVN ends the month between $11.68 and $16.59.
How big is Biohaven and what is its P/E ratio?
Biohaven's market capitalization is $1.9B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is BHVN?
ATLAS estimates annual volatility at 109%. In a typical month, half of the outcomes end between $11.68 and $16.59.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer